Evidence map›Paper›PMID 36792558›Full record

ReviewKorean circulation journal2023

Advancing Cardio-Oncology in Asia.

Choon Ta Ng, Li Ling Tan, Il Suk Sohn, Hilda Gonzalez Bonilla, Toru Oka, Teerapat Yinchoncharoen, Wei-Ting Chang, Jun Hua Chong, Maria Katrina Cruz Tan, Rochelle Regina Cruz and 6 more

Abstract readReview
In one paragraph

Review in Korean circulation journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Cardio-oncology in China.Current treatment options in oncology · 2023
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Choon Ta NgDepartment of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, MN, USA.ORCID https://orcid.org/0000-0002-3250-5076
Li Ling TanDepartment of Cardiology, National University Heart Centre Singapore, Singapore.ORCID https://orcid.org/0000-0002-0376-3674
Il Suk SohnDepartment of Cardiology, Kyung Hee University Hospital at Gangdong, Seoul, Korea.ORCID https://orcid.org/0000-0001-8004-5185
Hilda Gonzalez BonillaDepartment of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, MN, USA.ORCID https://orcid.org/0000-0002-1879-6647
Toru OkaOnco-Cardiology Unit, Department of Internal Medicine, Saitama Cancer Center, Saitama, Japan.ORCID https://orcid.org/0000-0002-5073-696X
Teerapat YinchoncharoenDepartment of Cardiology, Ramathibodi Hospital, Bangkok, Thailand.ORCID https://orcid.org/0000-0001-5689-2704
Wei-Ting ChangDivision of Cardiology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan.ORCID https://orcid.org/0000-0001-9132-5828
Jun Hua ChongDepartment of Cardiology, National Heart Centre Singapore, Singapore.ORCID https://orcid.org/0000-0002-3020-4851
Maria Katrina Cruz TanDepartment of Cardiology, St. Luke's Medical Center, Quezon, The Philippines.ORCID https://orcid.org/0000-0001-7265-0748
Rochelle Regina CruzDepartment of Cardiology, Cardinal Santos Medical Center, Metro Manila, The Philippines.ORCID https://orcid.org/0000-0003-3783-8192
Astri AstutiDepartment of Cardiology and Vascular Medicine, Hasan Sadikin General Hospital, Bandung, Indonesia.ORCID https://orcid.org/0000-0002-3598-6442
Vivek AgarwalaDepartment of Medical Oncology and Haemato-Oncology, Narayana Superspeciality Hospital and Cancer Institute, Howrah, India.ORCID https://orcid.org/0000-0003-1381-0320
Van ChienDepartment of Cardiology, National Heart Institute, Hanoi, Vietnam.ORCID https://orcid.org/0000-0002-0965-3855
Jong-Chan YounSeoul St. Mary's Hospital, Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0003-0998-503X
Jieli TongDepartment of Cardiology, Tan Tock Seng Hospital, Singapore.ORCID https://orcid.org/0000-0002-2293-7764
Joerg HerrmannDepartment of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, MN, USA. Herrmann.Joerg@mayo.edu.ORCID https://orcid.org/0000-0001-6675-4559

Funding

TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) TrialR01CA233610 · NCI · MAYO CLINIC ROCHESTER · PI HERRMANN, JOERG, RUDDY, KATHRYN JEAN · 2019 to 2024
$4.3M
Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell LymphomaR01CA233601 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI DUCKETT, DEREK RONALD, QI, JUN · 2020 to 2024
$2.5M
NCI NIH HHS R01 CA233601NCI NIH HHS R01 CA233610
6 · The paper itself

Abstract

Cardio-oncology is an emerging multi-disciplinary field, which aims to reduce morbidity and mortality of cancer patients by preventing and managing cancer treatment-related cardiovascular toxicities. With the exponential growth in cancer and cardiovascular diseases in Asia, there is an emerging need for cardio-oncology awareness among physicians and country-specific cardio-oncology initiatives. In this state-of-the-art review, we sought to describe the burden of cancer and cardiovascular disease in Asia, a region with rich cultural and socio-economic diversity. From describing the uniqueness and challenges (such as socio-economic disparity, ethnical and racial diversity, and limited training opportunities) in establishing cardio-oncology in Asia, and outlining ways to overcome any barriers, this article aims to help advance the field of cardio-oncology in Asia.

Indexed as

AsiaCancerCardio-oncologyCardiotoxicityOnco-cardiology

Identifiers

PMID36792558
PMCPMC9932224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.